By Ana Espino | Published on April 17, 2026 | 4 min read
Chagas disease, or American
trypanosomiasis, is a parasitic infection caused by Trypanosoma cruzi,
mainly transmitted by blood-feeding insect vectors. It progresses in two
phases: an acute phase that is often asymptomatic, followed by a chronic phase
that, in some patients, can lead to severe and potentially fatal cardiac or
digestive complications. Today, several million people remain infected,
primarily in Latin America, although the disease is becoming increasingly
global due to migration and environmental changes.
Despite decades of research,
therapeutic options remain limited. Available treatments show variable
efficacy, particularly in the chronic phase, and are associated with
significant adverse effects. Moreover, no vaccine is currently available. This
situation highlights major limitations in current management, particularly the
inability to sustainably prevent infection or halt disease progression.
The main challenges lie in
understanding the complex interactions between the parasite and the host immune
system. T. cruzi is capable of deploying sophisticated immune evasion
strategies, allowing it to persist long-term within the host.
In this context, this review,
recently published by Oxford University Press, was conducted to analyze host
immune responses, parasite evasion mechanisms, and recent advances in vaccine
development, in order to identify avenues for better disease control.
How does the parasite evade our
defenses ?
This study is based on an in-depth
analysis of existing data regarding:
• innate and adaptive immune responses to T. cruzi,
• parasite evasion mechanisms,
• the different vaccine approaches under development.
The data show that the body mounts
a robust immune response to infection. Innate immunity represents the first
line of defense, relying on recognition of the parasite via specific receptors
(TLRs), triggering an inflammatory cascade and activation of cells such as
macrophages and NK cells. At the same time, adaptive immunity mobilizes T
lymphocytes (Th1, Th17, CD8+) and B lymphocytes, enabling a coordinated
cellular and humoral response against the parasite.
However, despite this response,
complete elimination of the parasite is rarely achieved. T. cruzi
employs particularly effective evasion strategies. It disrupts immune signaling
pathways, inhibits complement activation, and promotes a tolerant immunological
environment. Notably, it can induce anti-inflammatory responses (Th2,
regulatory cells) that reduce the effectiveness of host defenses and favor
chronic persistence.
In the face of these obstacles,
vaccine development represents a major avenue. Several innovative approaches
are currently being explored:
• attenuated vaccines using CRISPR-Cas9, capable of inducing strong and durable
immune responses,
• DNA vaccines targeting key antigens such as cruzipain,
• recombinant protein vaccines, some already in early clinical phases,
• mRNA vaccines, inspired by recent technologies, showing promising immune
responses in preclinical models.
Overall, these strategies
demonstrate the ability to reduce parasite burden and induce protective immune
responses, but most remain at the preclinical stage.
Vaccine hope in progress
Chagas disease remains a major
parasitic infection, characterized by chronic progression and severe
complications. Key challenges include the parasite’s ability to evade the
immune system, persistence of infection, and the lack of effective preventive
strategies such as vaccination.
This review aimed to better
understand the interactions between T. cruzi and the immune system, and
to assess progress in vaccine development.
The results show that, despite an
initially effective immune response, the parasite succeeds in establishing
chronic infection through complex evasion mechanisms.
However, recent advances in vaccine technologies offer
promising perspectives for disease control. Future directions rely on a better
understanding of immune mechanisms and on the development of vaccines combining
multiple approaches. An integrated strategy, combining scientific innovation
and public health efforts, will be essential to control—or even eliminate—this
neglected tropical disease.
Read next: When
immunity suppresses appetite: decoding a gut–brain dialogue
About the author – Ana Espino
PhD in Immunology, specialized in Virology
As a scientific writer, Ana is passionate about bridging the gap
between research and real-world impact. With expertise in immunology, virology,
oncology, and clinical studies, she makes complex science clear and accessible.
Her mission: to accelerate knowledge sharing and empower evidence-based
decisions through impactful communication.
